Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Van Cutsem

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Seminars in Oncology|February 1, 1995
Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working PartyJ P Sculier, G Bureau, V Giner, et al.
Revue Des Maladies Respiratoires|January 1, 1994
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]J P Sculier, M Paesmans, G Bureau, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapyJ P Sculier, T Berghmans, J J Lafitte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working PartyJ P Sculier, M Paesmans, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working PartyJ Klastersky, J P Sculier, F Ries, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 1998
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working PartyM Paesmans, J P Sculier, P Libert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Cancer|August 10, 2000
Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 yearsM Paesmans, J P Sculier, J Lecomte, et al.
The European Respiratory Journal|May 31, 2011
Validation and comparison of several published prognostic systems for patients with small cell lung cancerM Paesmans, J J Lafitte, J Lecomte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, G Bureau, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Seminars in Oncology|February 1, 1995
Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working PartyJ P Sculier, G Bureau, V Giner, et al.
Revue Des Maladies Respiratoires|January 1, 1994
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]J P Sculier, M Paesmans, G Bureau, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapyJ P Sculier, T Berghmans, J J Lafitte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working PartyJ P Sculier, M Paesmans, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working PartyJ Klastersky, J P Sculier, F Ries, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 1998
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working PartyM Paesmans, J P Sculier, P Libert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Cancer|August 10, 2000
Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 yearsM Paesmans, J P Sculier, J Lecomte, et al.
The European Respiratory Journal|May 31, 2011
Validation and comparison of several published prognostic systems for patients with small cell lung cancerM Paesmans, J J Lafitte, J Lecomte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, M Paesmans, G Bureau, et al.
Pageof 3